HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Equipotent inhibition of fatty acid amide hydrolase and monoacylglycerol lipase - dual targets of the endocannabinoid system to protect against seizure pathology.

Abstract
Advances in the understanding of the endogenous cannabinoid system have led to several therapeutic indications for new classes of compounds that enhance cannabinergic responses. Endocannabinoid levels are elevated during pathogenic conditions, and inhibitors of endocannabinoid inactivation promote such on-demand responses. The endocannabinoids anandamide and 2-arachidonoyl glycerol have been implicated in protective signaling against excitotoxic episodes, including seizures. To better understand modulatory pathways that can exploit such responses, we used the new generation compound AM6701 that blocks both the anandamide-deactivating enzyme fatty acid amide hydrolase (FAAH) and the 2-arachidonoyl glycerol-deactivating enzyme monoacylglycerol lipase (MAGL) with equal potency. Also studied was the structural isomer AM6702 which is 44-fold more potent for inhibiting FAAH versus MAGL. When applied before and during kainic acid (KA) exposure to cultured hippocampal slices, AM6701 protected against the resulting excitotoxic events of calpain-mediated cytoskeletal damage, loss of presynaptic and postsynaptic proteins, and pyknotic changes in neurons. The equipotent inhibitor was more effective than its close relative AM6702 at protecting against the neurodegenerative cascade assessed in the slice model. In vivo, AM6701 was also the more effective compound for reducing the severity of KA-induced seizures and protecting against behavioral deficits linked to seizure damage. Corresponding with the behavioral improvements, cytoskeletal and synaptic protection was elicited by AM6701, as found in the KA-treated hippocampal slice model. It is proposed that the influence of AM6701 on FAAH and MAGL exerts a synergistic action on the endocannabinoid system, thereby promoting the protective nature of cannabinergic signaling to offset excitotoxic brain injury.
AuthorsVinogran Naidoo, David A Karanian, Subramanian K Vadivel, Johnathan R Locklear, JodiAnne T Wood, Mahmoud Nasr, Pamela Marie P Quizon, Emily E Graves, Vidyanand Shukla, Alexandros Makriyannis, Ben A Bahr
JournalNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics (Neurotherapeutics) Vol. 9 Issue 4 Pg. 801-13 (Oct 2012) ISSN: 1878-7479 [Electronic] United States
PMID22270809 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • AM 6701
  • Convulsants
  • Endocannabinoids
  • Enzyme Inhibitors
  • Tetrazoles
  • Monoacylglycerol Lipases
  • Amidohydrolases
  • fatty-acid amide hydrolase
Topics
  • Amidohydrolases (antagonists & inhibitors)
  • Animals
  • Convulsants (toxicity)
  • Endocannabinoids (metabolism)
  • Enzyme Inhibitors (pharmacology)
  • Hippocampus (drug effects, enzymology)
  • Immunoblotting
  • Male
  • Monoacylglycerol Lipases (antagonists & inhibitors)
  • Neurons (drug effects, enzymology)
  • Organ Culture Techniques
  • Rats
  • Rats, Sprague-Dawley
  • Seizures (enzymology)
  • Tetrazoles (toxicity)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: